Authors
Latest:
Pharma, FDA Wrestle with Social Media ToolsHealthcare discussions are booming on the Internet. How will FDA allow pharma to participate?
Latest:
Managing supply chains from the cloudNew IT data-science and visualization tools advance supply chain management
Latest:
The Time Is Right to Reform Your Approach to Managed CareNot all managed care plans have the same influence on overall prescribing behavior, and not all geographies operate the same way
Latest:
What manufacturers should anticipate when working with specialty pharmaciesWhen entering the specialty pharmaceuticals arena, manufacturers need to evaluate the capabilities of their channel partners carefully
Latest:
Improving medication adherence with technologyThe longstanding adherence problem is yielding to new technology
Latest:
Using patient journey insights to tailor delivery of servicesDeep analysis of specialty pharmacy data shows opportunities for managing the patient journey
Latest:
Varcode to Work with Avery Dennison on a Cold Chain Tracking ApplicationVarcode’s variable barcode records temperature and time out-of-compliance for pharma and perishables
Latest:
The power of strategic data standardizationGlobal efforts to collect clinical data in a more standardized form will lead to more research innovation
Latest:
Is your corporate board equipped to monitor incentive programs?Compliance officers at pharma companies need to ensure that the right mechanisms are in place for monitoring sales and business incentives
Latest:
Advances in clinical trial logisticsBetter local resources around the world and more sophisticated technology are changing the dynamics of logistics services
Latest:
Specialty pharmacy dynamicsThe SP channel continues to grow, with manufacturers looking for more control over access
Latest:
Bringing value to healthcare: practical steps for getting to a market-based modelA new, market-driven model of drug development and commercialization is appearing*
Latest:
DME competitive bidding issues: When is enough enough?Retailers, distributors and manufacturers are being affected by federal rules on durable medical equipment (DME)
Latest:
What Makes a Pharmaceutical Industry Leader?Personality assessments identify the traits that enable some pharma researchers to ascend to leadership roles in industry
Latest:
The end or just the beginning? Exploring federal preemption of state marketing and distribution lawsMultiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation
Latest:
Future look: The Impact of Biosimilars on OncologyMarketing strategies will adjust with the advent of biosimilars
Latest:
A managed services approach to sales and marketingApplying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize
Latest:
The end or just the beginning? Exploring federal preemption of state marketing and distribution lawsMultiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation
Latest:
Leveraging the EHR to Advance Clinical ResearchConverging the processes and data from EHRs and from the electronic data-capture (EDC) of the clinical research environment could change the paradigm of drug development and safety
Latest:
Building bridges to rare disease patientsOrphan drug development and marketing have important distinct requirements for R&D, regulatory and marketing
Latest:
The dynamic evolution of multi-sponsor REMSRisk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers
Latest:
Automated Contract Management Provides Substantial Benefits to Nektar TherapeuticsCLM Matrix system exploits Microsoft SharePoint platform
Latest:
Risky Business: What Life Sciences Need to Know About the US Foreign Corrupt Practices Act Before an AcquisitionNearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Latest:
PRIMES: The six key elements of successful drug/device developmentGuidance for companies starting out on the commercialization path
Latest:
Supreme Court: reverse payment settlements subject to antitrust scrutinyWhat are the risks of future 'pay for delay' settlements between branded and generic manufacturers?
